This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Shanghai Hutchison Pharmaceuticals Limited
Shanghai Hutchison Pharmaceuticals Limited, often referred to as SHPL, is a prominent player in the pharmaceutical industry, headquartered in Shanghai, China. Established in 1995, the company has made significant strides in the development and manufacturing of innovative healthcare solutions, focusing primarily on prescription medications and over-the-counter products. With a strong presence in both domestic and international markets, SHPL is dedicated to advancing therapeutic areas such as oncology, cardiology, and infectious diseases. The company is recognised for its commitment to quality and research, boasting a robust portfolio of unique formulations that cater to diverse patient needs. Notable achievements include strategic partnerships and a growing market share, positioning Shanghai Hutchison Pharmaceuticals as a leader in the competitive pharmaceutical landscape. Through its dedication to innovation and excellence, SHPL continues to enhance healthcare outcomes globally.
DitchCarbon Score
How does Shanghai Hutchison Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shanghai Hutchison Pharmaceuticals Limited's score of 36 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shanghai Hutchison Pharmaceuticals Limited, headquartered in CN, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of HUTCHMED (China) Limited, which may influence its climate-related initiatives and reporting. As of now, there are no documented reduction targets or climate pledges from Shanghai Hutchison Pharmaceuticals Limited. The absence of specific commitments or targets suggests that the company may still be in the early stages of developing its climate strategy. Given the lack of direct emissions data and reduction initiatives, it is essential for Shanghai Hutchison Pharmaceuticals Limited to consider establishing measurable climate commitments and targets to align with industry standards and enhance its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 14,000 | 000,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 2 | 5,073,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | 262,000 | 000,000 | - | 00,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shanghai Hutchison Pharmaceuticals Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
